Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2019 | Should we transplant or not in frontline therapy for MCL?

Tycel Phillips • 3 Jun 2019
ASCO 2019
Lymphoma Mantle Cell Lymphoma

Tycel Phillips, MD, of the University of Michigan, Ann Arbor, MI, discusses if we should transplant or not in frontline therapy for mantle cell lymphoma (MCL) at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Tycel Phillips

Long-term disease control associated with epcoritamab and CAR T-cell therapy in LBCL 2:15
Long-term disease control associated with epcoritamab and CAR T-cell therapy in LBCL
Tycel Phillips • 6 Dec 2025
The evolving paradigm of frontline DLBCL treatment: strategies being explored in trial 1:50
The evolving paradigm of frontline DLBCL treatment: strategies being explored in trial
Tycel Phillips • 6 Dec 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025

Related Videos

Preliminary findings from a trial of a novel CD30-directed antibody-drug conjugate in R/R lymphomas 1:57
Preliminary findings from a trial of a novel CD30-directed antibody-drug conjugate in R/R lymphomas
Swetha Thiruvengadam • 8 Dec 2025
Interim analysis of a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL 1:14
Interim analysis of a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL
Swetha Thiruvengadam • 8 Dec 2025
Primary Phase III results from the EPCORE FL-1 trial: epcoritamab plus R2 versus R2 for R/R FL 3:07
Primary Phase III results from the EPCORE FL-1 trial: epcoritamab plus R2 versus R2 for R/R FL
Lorenzo Falchi • 6 Dec 2025
Phase II trial of mosunetuzumab with response-driven lenalidomide augmentation in FL and MZL 3:05
Phase II trial of mosunetuzumab with response-driven lenalidomide augmentation in FL and MZL
Adam Olszewski • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals